|
Feb 15
|
AstraZeneca: IMFINZI improved event-free survival, OS across MIBC
|
|
Feb 15
|
2 Healthcare Stocks That Tumbled in 2024...but Could See an Impressive Comeback in 2025
|
|
Feb 14
|
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in post-hoc exploratory analysis of NIAGARA Phase III trial
|
|
Feb 14
|
Is AstraZeneca PLC (AZN) the Best Foreign Dividend Stock to Buy According to Analysts?
|
|
Feb 12
|
3 UK Stocks That May Be Undervalued Based On Current Estimates
|
|
Feb 12
|
AstraZeneca PLC (AZN): Among the Best International Dividend Stocks to Buy Now
|
|
Feb 11
|
Is AstraZeneca PLC (AZN) the Safest Dividend Stock in the UK?
|
|
Jan 4
|
Better Buy: Novo Nordisk vs. AstraZeneca
|
|
Jan 3
|
China’s NMPA prioritises HUTCHMED’s lung cancer therapy review
|
|
Jan 3
|
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and Pfizer
|
|
Jan 2
|
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
|
|
Jan 2
|
5 Large Drug Stocks to Keep An Eye On in the New Year
|
|
Dec 30
|
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Champions for 2024?
|
|
Dec 29
|
Is AstraZeneca PLC (AZN) Among the U.K. Dividend Aristocrats for 2024?
|
|
Oct 1
|
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
|
|
Sep 30
|
AstraZeneca (AZN): A Strong Buy as FDA Approves Key Cancer Treatments and Revenue Surges
|
|
Sep 30
|
Is AstraZeneca PLC (NASDAQ:AZN) The Top Global Stock To Buy Now?
|
|
Sep 29
|
Is AstraZeneca PLC (AZN) the Best Cheap Growth Stock to Buy According to Analysts?
|
|
Sep 28
|
15 Unhealthiest Countries in Europe
|
|
Sep 27
|
Pharma Stock Roundup: JNJ's 3rd Talc-Related Bankruptcy Filing & More
|